Biolex Therapeutics has entered into an agreement with Cook Pharmica under which Cook will manufacture drug substance for use in Biolex’s Phase III trials of Locteron. Locteron is a controlled-release interferon alpha 2b, designed to improve patient care with a more convenient dosing schedule and reduced side effects associated with pegylated interferons, the current standard of care. “We evaluated a number of potential contract manufacturers and were extremely impressed with the...